MaxCyte Bilanço Sağlığı

Finansal Sağlık kriter kontrolleri 6/6

MaxCyte şirketinin toplam hissedar öz sermayesi $213.3M ve toplam borcu $0.0 olup, bu da borç-öz sermaye oranını 0% seviyesine getiriyor. Toplam varlıkları ve toplam yükümlülükleri sırasıyla $248.6M ve $35.3M dir.

Anahtar bilgiler

Borç/özkaynak oranı

US$0

Borç

Faiz karşılama oranı	n/a
Nakit	US$153.83m
Eşitlik	US$213.30m
Toplam yükümlülükler	US$35.31m
Toplam varlıklar	US$248.61m

Son finansal sağlık güncellemeleri

Güncelleme yok

Recent updates

MaxCyte expands capacity by relocating to new HQ in Maryland

Sep 21

MaxCyte signs strategic platform with LG Chem

Jul 12

MaxCyte: Enabling Next-Generation Cell Based Therapies, Attractive Risk-Return Profile

Sep 06

Finansal Durum Analizi

Kısa Vadeli Yükümlülükler: MXCT 'nin kısa vadeli varlıkları ( $172.9M ) kısa vadeli yükümlülüklerini ( $17.6M ) aşıyor.

Uzun Vadeli Yükümlülükler: MXCT şirketinin kısa vadeli varlıkları ( $172.9M ) uzun vadeli yükümlülüklerini ( $17.7M ) aşmaktadır.

Borç-Özkaynak Tarihçesi ve Analizi

Borç Seviyesi: MXCT borçsuzdur.

Borcun Azaltılması: MXCT şirketinin 5 yıl önce borç/öz sermaye oranı 36% iken borcu yok.

Bilanço

Nakit Pist Analizi

Geçmişte ortalama olarak zarar eden şirketler için, en az 1 yıllık nakit akışına sahip olup olmadıklarını değerlendiriyoruz.

İstikrarlı Nakit Pisti: MXCT şirketinin mevcut serbest nakit akışına göre 3 yıldan fazla bir süre için yeterli nakit pistine sahip olduğu belirtiliyor.

Tahmini Nakit Akışı: MXCT, serbest nakit akışı her yıl % 21.3 oranında tarihi oranda azalmaya devam ederse 3 yıldan fazla bir süre yeterli nakit akışına sahip olur

MaxCyte Bilanço Sağlığı

Finansal Sağlık kriter kontrolleri 6/6

Anahtar bilgiler

Son finansal sağlık güncellemeleri

Recent updates

Third quarter 2024 earnings: EPS and revenues exceed analyst expectations

MaxCyte, Inc. Updates Revenue Guidance for the Full Year 2024

MaxCyte, Inc. Announces Appointment of Cynthia Collins as Non-Executive Director

MaxCyte, Inc. to Report Q3, 2024 Results on Nov 06, 2024

MaxCyte, Inc. Appoints Ali Soleymannezhad as Chief Commercial Officer

Second quarter 2024 earnings: EPS and revenues exceed analyst expectations

MaxCyte, Inc. Reaffirms Revenue Guidance for the Full Year 2024

New minor risk - Share price stability

MaxCyte, Inc. to Report Q2, 2024 Results on Aug 06, 2024

MaxCyte, Inc.(NasdaqGS:MXCT) dropped from Russell 2500 Growth Index

President recently bought US$489k worth of stock

Maxcyte, Inc. Affirms Revenue Guidance for the Full Year 2024

Price target decreased by 7.1% to US$8.67

MaxCyte, Inc., Annual General Meeting, Jun 11, 2024

MaxCyte, Inc. to Report Q1, 2024 Results on May 07, 2024

MaxCyte, Inc. Reiterates Earnings Guidance for the Year 2024

Full year 2023 earnings: EPS and revenues exceed analyst expectations

MaxCyte, Inc. Provides Revenue Guidance for the Fiscal Year 2023 and 2024

MaxCyte, Inc. to Report Fiscal Year 2023 Results on Mar 12, 2024

MaxCyte, Inc. Announces Departure of Cenk Sumen as Chief Scientific Officer

MaxCyte, Inc. Provides Preliminary Financial Guidance for the Fourth Quarter and Full Year Ended December 31, 2023

MaxCyte, Inc. Provides Revenue Guidance Update for 2023

New major risk - Revenue and earnings growth

MaxCyte, Inc. Provides Revenue Guidance for the Year 2023

Third quarter 2023 earnings: EPS and revenues miss analyst expectations

MaxCyte, Inc. Provides Revenue Guidance for the Third Quarter and Full Year of 2023

New minor risk - Share price stability

MaxCyte, Inc. to Report Q3, 2023 Results on Nov 08, 2023

Price target decreased by 9.5% to US$9.50

Maxcyte, Inc. Appoints Ali Soleymannezhad as Executive Vice President of Bioprocessing

New major risk - Revenue and earnings growth

Price target decreased by 9.5% to US$9.50

MaxCyte, Inc. Provides Revenue Guidance for the Year 2023

MaxCyte, Inc. to Report Q2, 2023 Results on Aug 09, 2023

First quarter 2023 earnings: EPS and revenues exceed analyst expectations

MaxCyte, Inc. Provides Revenue Guidance for the Year 2023

High number of new directors

Key Executive recently bought US$345k worth of stock

Full year 2022 earnings released: US$0.23 loss per share (vs US$0.21 loss in FY 2021)

MaxCyte, Inc. to Report Q4, 2022 Results on Mar 15, 2023

Price target decreased to US$11.67

MaxCyte, Inc. Appoints Patrick J. Balthrop, Sr. as Class II Director and Member of Nominating Committee and Corporate Governance Committee

MaxCyte, Inc. Provides Revenue Guidance for 2022

Third quarter 2022 earnings: EPS and revenues exceed analyst expectations

MaxCyte, Inc. to Report Q3, 2022 Results on Nov 09, 2022

MaxCyte expands capacity by relocating to new HQ in Maryland

Maxcyte, Inc. Revenue Guidance for 2022

Second quarter 2022 earnings: EPS in line with analyst expectations despite revenue beat

MaxCyte, Inc. to Report Q2, 2022 Results on Aug 10, 2022

MaxCyte signs strategic platform with LG Chem

MaxCyte, Inc.(NasdaqGS:MXCT) dropped from Russell 2000 Growth Index

MaxCyte, Inc., Annual General Meeting, Jun 29, 2022

First quarter 2022 earnings: EPS and revenues exceed analyst expectations

MaxCyte, Inc. Provides Revenue Guidance for the Full Year 2022

MaxCyte, Inc. to Report Q1, 2022 Results on May 09, 2022

Maxcyte, Inc. Announces CFO Changes, Effective as of April 15, 2022

MaxCyte, Inc. to Report Q4, 2021 Results on Mar 22, 2022

Maxcyte, Inc. Provides Preliminary Earnings Guidance for the Fourth Quarter and Full Year Ended December 31, 2021

Independent Chairman of the Board recently bought US$222k worth of stock

Founder recently sold US$1.3m worth of stock

Third quarter 2021 earnings released: US$0.032 loss per share (vs US$0.037 loss in 3Q 2020)

Second quarter 2021 earnings released: US$0.052 loss per share (vs US$0.046 loss in 2Q 2020)

MaxCyte, Inc. Provides Preliminary Revenue Guidance for the Year 2021

MaxCyte: Enabling Next-Generation Cell Based Therapies, Attractive Risk-Return Profile

Forecast breakeven pushed back to 2023

Finansal Durum Analizi

Borç-Özkaynak Tarihçesi ve Analizi

Bilanço

Nakit Pist Analizi

Sağlıklı şirketleri keşfedin